CY1121017T1 - Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης - Google Patents

Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης

Info

Publication number
CY1121017T1
CY1121017T1 CY181101192T CY181101192T CY1121017T1 CY 1121017 T1 CY1121017 T1 CY 1121017T1 CY 181101192 T CY181101192 T CY 181101192T CY 181101192 T CY181101192 T CY 181101192T CY 1121017 T1 CY1121017 T1 CY 1121017T1
Authority
CY
Cyprus
Prior art keywords
piperidin
isopropoxy
chloro
phenyl
methyl
Prior art date
Application number
CY181101192T
Other languages
English (en)
Inventor
Lili Feng
Baoqing Gong
Piotr H Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121017(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1121017T1 publication Critical patent/CY1121017T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η παρούσα εφεύρεση περιγράφει κρυσταλλική μορφή 5-χλωρο-Ν-(2-ισοπροποξυ-5-μεθυλ-4-(πιπεριδιν-4-υλφαινυλ)-Ν-2-(ισοπροπυλσουλφονυλ)φαινυλ)-2,4-διαμίνης. Η παρούσα εφεύρεση περαιτέρω σχετίζεται με φαρμακευτικές συνθέσεις που περιλαμβάνουν τις εν λόγω κρυσταλλικές μορφές, και μεθόδους για χρήση των εν λόγω κρυσταλλικών μορφών και φαρμακευτικών συστατικών στη θεραπεία ασθένειας.
CY181101192T 2010-12-17 2018-11-09 Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης CY1121017T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
EP11806079.7A EP2651918B1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
PCT/US2011/065030 WO2012082972A1 (en) 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
CY1121017T1 true CY1121017T1 (el) 2019-12-11

Family

ID=45464892

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171101064T CY1119474T1 (el) 2010-12-17 2017-10-11 Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY181101192T CY1121017T1 (el) 2010-12-17 2018-11-09 Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171101064T CY1119474T1 (el) 2010-12-17 2017-10-11 Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης

Country Status (35)

Country Link
US (2) US9309229B2 (el)
EP (3) EP2651918B1 (el)
JP (1) JP5916752B2 (el)
KR (4) KR20130130022A (el)
CN (7) CN104262324A (el)
AR (2) AR084309A1 (el)
AU (1) AU2011343775B2 (el)
BR (1) BR112013015000A2 (el)
CA (1) CA2821102C (el)
CL (1) CL2013001723A1 (el)
CO (1) CO6801792A2 (el)
CY (2) CY1119474T1 (el)
DK (2) DK2651918T3 (el)
EC (1) ECSP13012770A (el)
ES (3) ES2643016T3 (el)
GT (1) GT201300153A (el)
HR (2) HRP20171477T1 (el)
HU (1) HUE041845T2 (el)
IL (1) IL226474A (el)
LT (2) LT2651918T (el)
MA (1) MA34771B1 (el)
MX (1) MX338210B (el)
MY (2) MY164810A (el)
NZ (1) NZ610713A (el)
PE (1) PE20140698A1 (el)
PL (2) PL2651918T3 (el)
PT (2) PT2651918T (el)
RS (1) RS57771B1 (el)
RU (2) RU2599785C3 (el)
SG (2) SG10201510082XA (el)
SI (2) SI3121171T1 (el)
TN (1) TN2013000216A1 (el)
TW (2) TWI576343B (el)
WO (1) WO2012082972A1 (el)
ZA (1) ZA201303599B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011343775B2 (en) 2010-12-17 2015-12-03 Novartis Ag Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
AU2013344049B2 (en) 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
TN2017000157A1 (en) 2014-10-21 2018-10-19 Ariad Pharma Inc Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (zh) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 色瑞替尼的晶型i及其制备方法
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (en) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2016098042A1 (en) * 2014-12-19 2016-06-23 Novartis Ag Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (zh) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 色瑞替尼的晶型及其制备方法
WO2017158619A1 (en) 2016-03-15 2017-09-21 Natco Pharma Limited A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
US20230348443A1 (en) * 2020-01-17 2023-11-02 Shandong Xuanzhu Pharma Co., Ltd. Crystal form of polycyclic anaplastic lymphoma kinase inhibitor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA06001759A (es) * 2003-08-15 2006-05-12 Novartis Ag 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios.
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CA2671744C (en) * 2006-12-08 2012-08-28 Irm Llc Compounds and compositions as protein kinase inhibitors
UA100846C2 (uk) 2006-12-08 2013-02-11 Айерем Елелсі Сполуки та композиція як інгібітори протеїнкінази
BRPI0815979A2 (pt) * 2007-08-28 2017-06-13 Irm Llc compostos e composições com inibidores de quinase, bem como uso dos mesmos
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
US8592432B2 (en) * 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
EP2440534A2 (en) * 2009-06-10 2012-04-18 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
JP2014501246A (ja) 2010-12-17 2014-01-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性アゾ環式アミド
AU2011343775B2 (en) 2010-12-17 2015-12-03 Novartis Ag Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl- 4-piperidin-4-yl-phenyl)-N4[2-(propane-2-sulfonyl)-phenyl] -pyrimidine-2,4-diamine
WO2012083306A2 (en) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (en) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Solid state forms of ceritinib and salts thereof
CN107107792B (zh) 2014-11-21 2020-05-19 Tk控股公司 气囊模块
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
JP2017537927A (ja) 2014-12-04 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ がん（骨髄腫）を処置するための抗ｃｓ１および抗ｐｄ１抗体の併用
WO2016098070A1 (en) 2014-12-19 2016-06-23 Novartis Ag Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
EP3328848A1 (en) 2015-07-28 2018-06-06 Zentiva, K.S. Solid forms of ceritinib free base
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
SG10201510082XA (en) 2016-01-28
PE20140698A1 (es) 2014-06-11
SI2651918T1 (sl) 2017-10-30
BR112013015000A2 (pt) 2016-08-09
CL2013001723A1 (es) 2013-12-27
KR20190022903A (ko) 2019-03-06
RU2016136823A (ru) 2018-12-11
AR122395A2 (es) 2022-09-07
US9309229B2 (en) 2016-04-12
TWI576344B (zh) 2017-04-01
ECSP13012770A (es) 2013-10-31
TWI576343B (zh) 2017-04-01
MY177742A (en) 2020-09-23
MX338210B (es) 2016-04-07
AU2011343775A1 (en) 2013-07-18
MA34771B1 (fr) 2013-12-03
ZA201303599B (en) 2014-02-26
NZ610713A (en) 2014-10-31
KR20180032680A (ko) 2018-03-30
CO6801792A2 (es) 2013-11-29
TW201307299A (zh) 2013-02-16
US20130274279A1 (en) 2013-10-17
DK3121171T3 (en) 2018-12-10
TN2013000216A1 (en) 2014-11-10
KR20200039021A (ko) 2020-04-14
IL226474A (en) 2016-03-31
RU2599785C3 (ru) 2019-04-24
RU2599785C2 (ru) 2016-10-20
EP2651918A1 (en) 2013-10-23
MY164810A (en) 2018-01-30
CN112125884A (zh) 2020-12-25
US20160175305A1 (en) 2016-06-23
PT3121171T (pt) 2018-11-27
EP3453708A1 (en) 2019-03-13
EP3453708B8 (en) 2022-03-16
KR20130130022A (ko) 2013-11-29
RU2746159C2 (ru) 2021-04-08
SI3121171T1 (sl) 2018-11-30
JP5916752B2 (ja) 2016-05-11
EP2651918B1 (en) 2017-07-12
CN114989139A (zh) 2022-09-02
RS57771B1 (sr) 2018-12-31
HRP20181737T1 (hr) 2018-12-28
CN106008462A (zh) 2016-10-12
EP3453708B1 (en) 2021-10-27
KR102325775B1 (ko) 2021-11-12
PT2651918T (pt) 2017-10-17
TW201629021A (zh) 2016-08-16
SG190856A1 (en) 2013-07-31
ES2643016T3 (es) 2017-11-21
IL226474A0 (en) 2013-07-31
MX2013006952A (es) 2013-07-15
CN103282359A (zh) 2013-09-04
PL3121171T3 (pl) 2019-01-31
AU2011343775B2 (en) 2015-12-03
AR084309A1 (es) 2013-05-08
ES2905973T3 (es) 2022-04-12
CN106831716A (zh) 2017-06-13
ES2696526T3 (es) 2019-01-16
RU2016136823A3 (el) 2020-02-06
CA2821102C (en) 2019-06-11
HRP20171477T1 (hr) 2017-11-17
GT201300153A (es) 2014-06-09
CA2821102A1 (en) 2012-06-21
WO2012082972A1 (en) 2012-06-21
CN104262324A (zh) 2015-01-07
EP3121171B1 (en) 2018-08-15
DK2651918T3 (en) 2017-10-23
HUE041845T2 (hu) 2019-05-28
CN107056751A (zh) 2017-08-18
CY1119474T1 (el) 2018-04-04
LT2651918T (lt) 2017-10-10
PL2651918T3 (pl) 2017-12-29
EP3121171A1 (en) 2017-01-25
RU2013132947A (ru) 2015-01-27
JP2013545812A (ja) 2013-12-26
LT3121171T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1123852T1 (el) Αλατα ή συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
EA201500953A1 (ru) 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений
CY1120008T1 (el) Βενζαμιδια
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201100623A1 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1119687T1 (el) Κρυσταλλικο αλας της (s)-(2-(6-χλωρο-7- μεθυλ-1η- βενζο [d]imiδazoλ-2- υλ)-2- μεθυλπυρρολιδιν-1- υλ)(5-μεθοξυ-2-(2η-1,2,3- τριαζολ-2- υλ)φαινυλ) μεθανονης ως ανταγωνιστης υποδοχεα ορεξινης
EA201691160A1 (ru) Антагонисты s1p3
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
AR073591A1 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas.
PA8798401A1 (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida